Misbadi (Dabigatran Etexilate)

Misbadi (dabigatran etexilate) is used in anticoagulation therapy to reduce thrombotic events in several cardiovascular conditions, particularly in adult patients safely.

• Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
• Deep vein thrombosis: treats acute DVT and helps prevent recurrence.
• Pulmonary embolism: treats acute PE and reduces risk of recurrent embolic events.
• Venous thromboembolism (VTE) prevention: maintains anticoagulation to lower incidence of new clots after initial therapy.
• Secondary prevention of VTE: continues therapy to avoid repeat DVT or PE episodes.

• Dabigatran etexilate is a prodrug that is rapidly converted to dabigatran, a reversible direct inhibitor of thrombin (factor IIa). By binding to the active site of thrombin, it blocks the conversion of fibrinogen to fibrin, preventing clot formation. The inhibition is independent of antithrombin and does not require cofactors, providing predictable anticoagulant effect across a wide range of patients in clinical practice.

Adverse reactions to Misbadi (dabigatran etexilate) are reported across clinical studies and post‑marketing surveillance.

Common Side Effects

• Dyspepsia: mild stomach discomfort, indigestion, or nausea.
• Gastrointestinal bleeding: minor bleeding such as melena or occult blood loss.
• Nosebleeds (epistaxis): occasional bleeding from the nasal passages.
• Bruising: easy bruising of the skin after minor trauma.
• Headache: transient, mild to moderate headache episodes.

Serious or Rare Side Effects

• Major bleeding: life‑threatening hemorrhage, including intracranial or gastrointestinal bleeding.
• Hepatic injury: signs of liver dysfunction, such as elevated